Career history of Douglas J. MacMaster
Former positions of Douglas J. MacMaster
| Companies | Position | Start | End |
|---|---|---|---|
Neose Technologies, Inc.
 Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Director/Board Member | 1992-12-31 | 2010-07-07 |
| MERCK & CO., INC. | Corporate Officer/Principal | 1960-12-31 | 1991-12-31 |
Martek Biosciences Corp.
 Martek Biosciences Corp. BiotechnologyHealth Technology Martek Biosciences Corp. developed, manufactured and marketed products derived from microalgae. The company was founded in 1985 and was headquartered in Columbia, MD. | Director/Board Member | 1992-12-31 | - |
Training of Douglas J. MacMaster
| St. Francis Xavier University | Undergraduate Degree |
| Boston College | Graduate Degree |
Statistics
International
| United States | 5 |
| Canada | 2 |
Operational
| Director/Board Member | 2 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Private companies | 2 |
|---|---|
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Health Technology |
Martek Biosciences Corp.
Martek Biosciences Corp. BiotechnologyHealth Technology Martek Biosciences Corp. developed, manufactured and marketed products derived from microalgae. The company was founded in 1985 and was headquartered in Columbia, MD. | Health Technology |
- Stock Market
- Insiders
- Douglas J. MacMaster
- Experience
